IONIS PHARMACEUTICALS INC·4

Feb 10, 5:04 PM ET

Monia Brett P 4

4 · IONIS PHARMACEUTICALS INC · Filed Feb 10, 2026

Research Summary

AI-generated summary of this filing

Updated

Ionis (IONS) CEO Monia Brett Sells 29,430 Shares

What Happened

  • Monia Brett P, Chief Executive Officer of Ionis Pharmaceuticals (IONS), sold 29,430 shares on 2026-02-06 in an open-market transaction for total proceeds of $2,524,820. The weighted-average sale price reported was $85.79 per share (individual trades ranged $85.22–$86.055). This was a sale (routine monetization), not a purchase.

Key Details

  • Transaction date: 2026-02-06; Form 4 filed 2026-02-10 (filing appears timely).
  • Price: weighted average $85.79; range $85.22 to $86.055 across multiple trades (per footnote).
  • Shares sold: 29,430; proceeds: $2,524,820.
  • Footnotes: sale executed pursuant to a Rule 10b5-1 trading plan adopted Aug 13, 2024; detailed per-price breakdown available upon request per filing.
  • Shares owned after transaction: not specified in the summary provided here — see the filed Form 4 for current beneficial ownership details.

Context

  • Sales under an established Rule 10b5-1 plan are typically pre-scheduled and can be routine (do not necessarily indicate management’s view of the company’s near-term prospects).
  • For retail investors: purchases by insiders often carry more immediate informational weight than routine sales, but tracking patterns of insider buying/selling over time can still be informative.

Insider Transaction Report

Form 4
Period: 2026-02-06
Monia Brett P
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-02-06$85.79/sh29,430$2,524,820254,497 total
Footnotes (2)
  • [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.22 to $86.055 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia|2026-02-09

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT